Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of Intravaginal Tamoxifen (DARE-VVA1): Randomized, Double-blind, Placebo-controlled Study of Safety, Pharmacokinetics and Pharmacodynamics in Postmenopausal Participants With Moderate to Sever Vulvar and Vaginal Atrophy

NCT05378269 is registered in ClinicalTrials.gov with Daré Bioscience, Inc. as lead sponsor.

NCT NCT05378269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05378269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of Intravaginal Tamoxifen (DARE-VVA1): Randomized, Double-blind, Placebo-controlled Study of Safety, Pharmacokinetics and Pharmacodynamics in Postmenopausal Participants With Moderate to Sever Vulvar and Vaginal Atrophy
Lead sponsor
Daré Bioscience, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
November 22, 2021
Completion date
March 1, 2023
Enrollment
17 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

vulvar atrophy